Therapeutic Asset Ratings

3,272 results matching 1 filter

91,565 assets7,904 sponsors3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Immunotherapic Bifunctional Fusion Protein Comprised Of A Fully Human Igg1 Monoclonal Antibody (Avelumab) Against Human Programmed Death-Ligand 1 (Pd-L1) Fused To The Soluble Extracellular Domain Of Transforming Growth Factor-.Beta. (Tgf-.Beta.) Receptor Ii, Which Acts As A Tgf-.Beta. Trap Penile Cancer	National Cancer Institute (NCI)	P1/2	CC (42)
SX682 Head And Neck Squamous Cell Carcinoma	National Cancer Institute (NCI)	P1/2	CC (42)
Valemetostat Head And Neck Cancer	National Cancer Institute (NCI)	P1/2	CC (42)
cd22 car-transduced t cells B-Cell Acute Lymphoblastic Leukemia	National Cancer Institute (NCI)	P2	CC (41)
Revumenib Acute Myeloid Leukemia, MLL Gene Rearrangement	National Cancer Institute (NCI)	P2	CC (41)
[212pb]vmt-alpha-net Nasopharyngeal Carcinoma	National Cancer Institute (NCI)	P1	CC (41)
Anetumab Ravtansine Malignant Pancreatic Neoplasm	National Cancer Institute (NCI)	P1	CC (41)
Autologous Ccr4 Car T Cells Anaplastic Large Cell Lymphoma	National Cancer Institute (NCI)	P1	CC (41)
Cabozantinib Multiple Sclerosis	National Cancer Institute (NCI)	P1	CC (41)
Cedazuridine Triple-Negative Breast Carcinoma	National Cancer Institute (NCI)	P1	CC (41)
Ceralasertib Colorectal Carcinoma	National Cancer Institute (NCI)	P1	CC (41)
Elimusertib Colorectal Carcinoma	National Cancer Institute (NCI)	P1	CC (41)
Elimusertib Lung Cancer	National Cancer Institute (NCI)	P1	CC (41)
Elimusertib Malignant Pancreatic Neoplasm	National Cancer Institute (NCI)	P1	CC (41)
Falimarev Pancreatic Adenocarcinoma	National Cancer Institute (NCI)	P1	CC (41)
Grt-R904 Digestive System Cancer	National Cancer Institute (NCI)	P1	CC (41)
Immunotherapic Bifunctional Fusion Protein Comprised Of A Fully Human Igg1 Monoclonal Antibody (Avelumab) Against Human Programmed Death-Ligand 1 (Pd-L1) Fused To The Soluble Extracellular Domain Of Transforming Growth Factor-.Beta. (Tgf-.Beta.) Receptor Ii, Which Acts As A Tgf-.Beta. Trap Urinary Bladder Carcinoma	National Cancer Institute (NCI)	P1	CC (41)
Immunotherapic Bifunctional Fusion Protein Comprised Of A Fully Human Igg1 Monoclonal Antibody (Avelumab) Against Human Programmed Death-Ligand 1 (Pd-L1) Fused To The Soluble Extracellular Domain Of Transforming Growth Factor-.Beta. (Tgf-.Beta.) Receptor Ii, Which Acts As A Tgf-.Beta. Trap Urothelial Carcinoma	National Cancer Institute (NCI)	P1	CC (41)
Inalimarev Pancreatic Adenocarcinoma	National Cancer Institute (NCI)	P1	CC (41)
pds01adc Malignant Urinary System Neoplasm	National Cancer Institute (NCI)	P1	CC (41)
pds01adc Urothelial Carcinoma	National Cancer Institute (NCI)	P1	CC (41)
Polatuzumab Burkitt Lymphoma	National Cancer Institute (NCI)	P1	CC (41)
Pomalidomide Burkitt Lymphoma	National Cancer Institute (NCI)	P1	CC (41)
Ropidoxuridine Bile Duct Carcinoma	National Cancer Institute (NCI)	P1	CC (41)
Ropidoxuridine Hematopoietic And Lymphoid Cell Neoplasm	National Cancer Institute (NCI)	P1	CC (41)

Showing 3101 to 3125 of 3,272 assets

PreviousPage 125 of 131Next